Healthcare
Live Price
Offline$243.82
-15.40% today
1Y Change
+11.27%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 254 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sartorius AG (SUVPF) is a Healthcare stock with a market cap of $15.00B and listed on OTC. The stock last traded around $243.82 and up 11.3% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +4.6%, EPS growth of +84.4%, a dividend yield of 0.3%. What stands out right now is revenue +4.6%, EPS +84.4%, free cash flow -62.2% with operating margin 16.5% and ROIC 4.6%. The dividend is present but secondary, with a yield around 0.3%. Valuation already assumes a fairly strong business story at P/E 92.2 and price/sales 4.2. Stock Foundry combines SUVPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SUVPF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SUVPF Max Drawdown
-23.70%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SUVPF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.4B
-17.4% YoY
FY Net Income
$318.9M
-53.0% YoY
Free Cash Flow
$458.6M
+116.8% YoY
Revenue Growth
+4.6%
EPS Growth
+84.4%
Gross Margin
45.6%
Net Margin
4.6%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.5B | 3.4B | 3.4B | 4.2B | 3.4B |
| Gross Profit | 1.6B | 1.5B | 1.6B | 2.2B | 1.8B |
| Operating Income | 651M | 437M | 543M | 1.1B | 736M |
| EBITDA | 1.1B | 787M | 873M | 1.5B | 927M |
| Net Income | 155M | 84M | 205M | 678M | 319M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 541M | 813M | 379M | 166M | 343M |
| Total Assets | 9.7B | 10.1B | 9.8B | 7.0B | 5.7B |
| Total Liabilities | 5.8B | 6.2B | 7.0B | 4.3B | 4.0B |
| Shareholder Equity | 2.7B | 2.8B | 2.1B | 2.0B | 1.3B |
| Total Debt | 4.5B | 4.6B | 5.3B | 2.5B | 2.1B |
| Net Debt | 3.9B | 3.7B | 4.9B | 2.4B | 1.7B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
866M
+17.9% YoY
Capital Expenditures
407M
+22.1% YoY
Free Cash Flow
459M
+116.8% YoY
Key ratios
Gross Margin
45.6%
Operating Margin
16.5%
Net Margin
4.6%
ROE
6.0%
Debt / Equity
1.58x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.